A proven team, backed by Blackstone
Uniquity Bio was built by a leadership team with decades of experience in immunology and inflammation and a successful track record advancing clinical programs through development to commercialization. As a Blackstone Life Sciences portfolio company, we have the expertise and committed capital to support a valuable and dynamic pipeline of high-potential medicines along with a range of partnership structures for maximum value.
BUILDING A DYNAMIC I&I PIPELINE
We’re actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no treatment options.
Our first lead asset is solrikitug, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), in which we aim to deliver best-in-class efficacy in several critical respiratory and gastrointestinal (GI) indications, including chronic obstructive pulmonary disease (COPD) and asthma.